EP2753331A1 - Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible - Google Patents

Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible

Info

Publication number
EP2753331A1
EP2753331A1 EP11757513.4A EP11757513A EP2753331A1 EP 2753331 A1 EP2753331 A1 EP 2753331A1 EP 11757513 A EP11757513 A EP 11757513A EP 2753331 A1 EP2753331 A1 EP 2753331A1
Authority
EP
European Patent Office
Prior art keywords
methanesulfonamide
dioxo
dihydro
quinazolin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11757513.4A
Other languages
German (de)
English (en)
Inventor
Klaus KUCHER
Donald Johns
George IMBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of EP2753331A1 publication Critical patent/EP2753331A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

La présente invention concerne l'utilisation d'antagonistes de compétition du récepteur AMPA pour le traitement ou la prévention de l'épilepsie photosensible.
EP11757513.4A 2011-09-07 2011-09-07 Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible Withdrawn EP2753331A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (fr) 2011-09-07 2011-09-07 Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible

Publications (1)

Publication Number Publication Date
EP2753331A1 true EP2753331A1 (fr) 2014-07-16

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11757513.4A Withdrawn EP2753331A1 (fr) 2011-09-07 2011-09-07 Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible

Country Status (10)

Country Link
EP (1) EP2753331A1 (fr)
JP (1) JP2014525474A (fr)
KR (1) KR20140071405A (fr)
CN (1) CN103889427A (fr)
AU (1) AU2011376333A1 (fr)
BR (1) BR112014005210A2 (fr)
CA (1) CA2846503A1 (fr)
IN (1) IN2014DN01791A (fr)
MX (1) MX2014002693A (fr)
WO (1) WO2013036224A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
WO2017117569A1 (fr) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2549967A1 (fr) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
EP1677788A1 (fr) 2003-10-31 2006-07-12 AstraZeneca AB Alcynes iii
EP1677790A1 (fr) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
EP1715867A4 (fr) 2004-02-12 2009-04-15 Merck & Co Inc Amides bipyridyles en tant que modulateurs du r cepteur-5 metabotropique du glutamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
EP1966144A1 (fr) 2005-12-20 2008-09-10 Novartis AG Dérivés d'acide nicotinique en tant que modulateurs des récepteurs métabotropiques du glutamate
BR112012010201A2 (pt) * 2009-11-03 2017-08-08 Lupin Ltd formulação de libertação modificada da lacosamida

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013036224A1 *

Also Published As

Publication number Publication date
BR112014005210A2 (pt) 2017-03-21
CN103889427A (zh) 2014-06-25
IN2014DN01791A (fr) 2015-05-15
WO2013036224A1 (fr) 2013-03-14
CA2846503A1 (fr) 2013-03-14
JP2014525474A (ja) 2014-09-29
MX2014002693A (es) 2014-06-04
KR20140071405A (ko) 2014-06-11
AU2011376333A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
Trenité et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
US10111889B2 (en) Uses of ganaxolone
Rogawski et al. Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist
DE60109589T2 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
AU2008271026A1 (en) A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-B) indoles, its pharmacological compound and application method
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US7226949B2 (en) Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
AU2016289271A1 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
JP2020143159A (ja) スミス‐マゲニス症候群を治療するためのタシメルテオン
EP2340254B1 (fr) Compositions et procédés pour traiter l épilepsie
WO2013036224A1 (fr) Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible
CN111801096B (zh) 癫痫治疗剂
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
EA023728B1 (ru) Терапевтическое средство от тревожных расстройств
Herrling et al. D-CPPene (SDZ EAA-494)—a competitive NMDA antagonist: pharmacology and results in humans
US20090270373A1 (en) Treatment of down syndrom with benzodiazepine receptor antagonists
CN111050800B (zh) 血清素3受体激动剂对疼痛的治疗
KR20120052341A (ko) 신경 세로이드 리포푸스신증의 치료에 사용하기 위한 1ｈ-퀴나졸린-2,4-디온
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
Hemanthkumar Study of anticonvulsant activity of acetazolamide on albino rats and its influence on anticonvulsant activity of sodium valproate
Kamath Study of Anticonvulsant effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model In Albino Mice
MX2012015090A (es) Uso de 1h-quinazolina-2,4-dionas.
ZA200509646B (en) Further therapeutic use of zolpidem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150825